Floatz logo

azd9592

Head and Neck Neoplasms

AstraZenecaPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Head and Neck Neoplasms cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BB
Pembrolizumab
Mayo Clinic
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 3BB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4B
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3B

View all 44 →

Same molecule, other indications

azd9592 is also rated in:

Advanced Solid TumoursDormant
CC
Indicative ·
43 / 100
View asset →
colorectal neoplasmDormant
C
Indicative ·
39 / 100
View asset →
neoplasmDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →